1
|
Boutas I, Sofoudis C, Kalampokas E,
Anastasopoulos C, Kalampokas T and Salakos N: Fertility
preservation in women with early stage cervical cancer. Review of
the literature. Eur J Gynaecol Oncol. 35:373–377. 2014.PubMed/NCBI
|
2
|
Arimoto T, Kawana K, Adachi K, Ikeda Y,
Nagasaka K, Tsuruga T, Yamashita A, Oda K, Ishikawa M, Kasamatsu T,
et al: Minimization of curative surgery for treatment of early
cervical cancer: A review. Jpn J Clin Oncol. 45:611–616. 2015.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Huang QT, Zhong M, Gao YF, Huang LP, Huang
Q, Wang W, Wang ZJ and Yu YH: Can HPV vaccine have other health
benefits more than cancer prevention? A systematic review of
association between cervical HPV infection and preterm birth. J
Clin Virol. 61:321–328. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mann L, Foley KL, Tanner AE, Sun CJ and
Rhodes SD: Increasing cervical cancer screening among us
hispanics/latinas: A qualitative systematic review. J Cancer Educ.
30:374–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Jiang J, Pang H, Liu B, Nasca PC, Zhang B,
Wu Y, Han W, Gates M, Lu T, Zou X, et al: Effects of active,
passive, and combined smoking on cervical cancer mortality: A
nationwide proportional mortality study in Chinese urban women.
Cancer Causes Control. 26:983–991. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Maguire R, Kotronoulas G, Simpson M and
Paterson C: A systematic review of the supportive care needs of
women living with and beyond cervical cancer. Gynecol Oncol.
136:478–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Li H, Wu X and Cheng X: Advances in
diagnosis and treatment of metastatic cervical cancer. J Gynecol
Oncol. 27:e432016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Obel J, Souares Y, Hoy D, Baravilala W,
Garland SM, Kjaer SK and Roth A: A systematic review of cervical
cancer incidence and mortality in the Pacific Region. Asian Pac J
Cancer Prev. 15:9433–9437. 2014. View Article : Google Scholar : PubMed/NCBI
|
9
|
Gadducci A, Tana R, Cosio S and Cionini L:
Treatment options in recurrent cervical cancer (Review). Oncol
Lett. 1:3–11. 2010.PubMed/NCBI
|
10
|
Smits RM, Zusterzeel PL and Bekkers RL:
Pretreatment retroperitoneal para-aortic lymph node staging in
advanced cervical cancer: A review. Int J Gynecol Cancer.
24:973–983. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lorusso D, Petrelli F, Coinu A,
Raspagliesi F and Barni S: A systematic review comparing cisplatin
and carboplatin plus paclitaxel-based chemotherapy for recurrent or
metastatic cervical cancer. Gynecol Oncol. 133:117–123. 2014.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Turan T, Yildirim BA, Tulunay G, Boran N,
Yıldız F and Köse MF: Experience in stage IB2 cervical cancer and
review of treatment. J Turk Ger Gynecol Assoc. 11:27–37.
2010.PubMed/NCBI
|
13
|
Sun R, Jiang B, Qi H, Zhang X, Yang J,
Duan J, Li Y and Li G: SOX4 contributes to the progression of
cervical cancer and the resistance to the chemotherapeutic drug
through ABCG2. Cell Death Dis. 6:e19902015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Andersson U, Erlandsson-Harris H, Yang H
and Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol.
72:1084–1091. 2002.PubMed/NCBI
|
15
|
Kang R, Zhang Q, Zeh HJ III, Lotze MT and
Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res.
19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Lolmede K, Campana L, Vezzoli M, Bosurgi
L, Tonlorenzi R, Clementi E, Bianchi ME, Cossu G, Manfredi AA,
Brunelli S and Rovere-Querini P: Inflammatory and alternatively
activated human macrophages attract vessel-associated stem cells,
relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc
Biol. 85:779–787. 2009. View Article : Google Scholar : PubMed/NCBI
|
17
|
Szénási T, Kénesi E, Nagy A, Molnár A,
Bálint BL, Zvara Á, Csabai Z, Deák F, Boros Oláh B, Mátés L, et al:
Hmgb1 can facilitate activation of the matrilin-1 gene promoter by
Sox9 and L-Sox5/Sox6 in early steps of chondrogenesis. Biochim
Biophys Acta. 1829:1075–1091. 2013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Galluzzi L, Pietrocola F, Bravo-San Pedro
JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J,
Gewirtz DA, Karantza V, et al: Autophagy in malignant
transformation and cancer progression. EMBO J. 34:856–880. 2015.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Berardi DE, Campodónico PB, Díaz Bessone
MI, Urtreger AJ and Todaro LB: Autophagy: Friend or foe in breast
cancer development, progression and treatment. Int J Breast Cancer.
2011:5950922011.PubMed/NCBI
|
20
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xie M, Kang R, Yu Y, Zhu S, He YL, Xu WQ,
Tang DL and Cao LZ: Enhancive effect of HMGB1 gene silence on
adriamycin-induced apoptosis in K562/A02 drug resistance leukemia
cells. Zhonghua Xue Ye Xue Za Zhi. 29:549–552. 2008.(In Chinese).
PubMed/NCBI
|
22
|
Suren D, Yıldırım M, Demirpençe Ö, Kaya V,
Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high
mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit.
20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Gnanasekar M, Kalyanasundaram R, Zheng G,
Chen A, Bosland MC and Kajdacsy-Balla A: HMGB1: A Promising
therapeutic target for prostate cancer. Prostate Cancer.
2013:1571032013.PubMed/NCBI
|
24
|
Zhang X, Wang H and Wang J: Expression of
HMGB1 and NF-κB p65 and its significance in non-small cell lung
cancer. Contemp Oncol (Pozn). 17:350–355. 2013.PubMed/NCBI
|
25
|
Ohmori H, Luo Y and Kuniyasu H:
Non-histone nuclear factor HMGB1 as a therapeutic target in
colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Lee H, Shin N, Song M, Kang UB, Yeom J,
Lee C, Ahn YH, Yoo JS, Paik YK and Kim H: Analysis of nuclear high
mobility group box 1 (HMGB1)-binding proteins in colon cancer
cells: Clustering with proteins involved in secretion and
extranuclear function. J Proteome Res. 9:4661–4670. 2010.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Bukowska-Durawa A and Luszczynska A:
Cervical cancer screening and psychosocial barriers perceived by
patients. A systematic review. Contemp Oncol (Pozn). 18:153–159.
2014.PubMed/NCBI
|
28
|
Kavallaris A, Zygouris D, Dafopoulos A,
Kalogiannidis I and Terzakis E: Nerve sparing radical hysterectomy
in early stage cervical cancer. Latest developments and review of
the literature. Eur J Gynaecol Oncol. 36:5–9. 2015.PubMed/NCBI
|
29
|
Chen S, Li X, Feng J, Chang Y, Wang Z and
Wen A: Autophagy facilitates the Lapatinib resistance of HER2
positive breast cancer cells. Med Hypotheses. 77:206–208. 2011.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Yu L, Gu C, Zhong D, Shi L, Kong Y, Zhou Z
and Liu S: Induction of autophagy counteracts the anticancer effect
of cisplatin in human esophageal cancer cells with acquired drug
resistance. Cancer Lett. 355:34–45. 2014. View Article : Google Scholar : PubMed/NCBI
|